Company news
Sunshine Biopharma Inc. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Sunshine Biopharma Has Launched Nine New Generic Prescription Drugs in 2024: Now Marketing Sixty-One Generic Drugs in Canada
August 25, 2024
Sunshine Biopharma reports 2024 second quarter results, second qtr revenues up 67%, YTD revenues up 61%
August 20, 2024
Sunshine Biopharma Reports 2024 Second Quarter Results: Second QTR Revenues up 67%, YTD Revenues up 61%
August 18, 2024
Sunshine Biopharma Announces Reverse Stock Split
August 5, 2024
Sunshine Biopharma Reports 2024 First Quarter Results: Revenues Up 54%
May 20, 2024
Sunshine Biopharma's Nora Pharma Receives Health Canada Approval for Niopeg, a Biosimilar of Neulasta
April 22, 2024
Sunshine Biopharma's Nora Pharma Receives Health Canada Approval for Niopeg(R), a Biosimilar of Neulasta(R)
April 18, 2024
Sunshine Biopharma Announces Reverse Stock Split
April 11, 2024
Sunshine Biopharma Reports Operating Results for the Fiscal Year Ended December 31, 2023
March 31, 2024
Sunshine Biopharma, Inc. Announces Closing of $10.0 Million Underwritten Public Offering
February 14, 2024
Sunshine Biopharma, Inc. Announces Pricing of $10.0 Million Underwritten Public Offering
February 12, 2024
Sunshine Biopharma Moves Principal Office to New York City
December 3, 2023
Sunshine Biopharma Reports 2023 Third Quarter Results: Revenues up Significantly Over Last Year Due to a Key Acquisition
November 12, 2023
Sunshine Biopharma Reports 2023 Second Quarter Results: Revenues Up 3,600%
August 10, 2023
Sunshine Biopharma Announces Closing of $5.0 Million Private Placement Priced At-the-Market
May 15, 2023
Sunshine Biopharma Announces Pricing of $5.0 Million Private Placement Priced At-the-Market
May 11, 2023
Sunshine Biopharma Reports 2023 First Quarter Results: Revenues Up 2,100%
May 10, 2023
Sunshine Biopharma Reports Full Year Ended December 31, 2022 Financial Results and Provides Corporate Update
April 4, 2023
Sunshine Biopharma Signs Exclusive Worldwide License With University of Arizona For PLpro-Based Covid-19 Treatment
February 27, 2023
Sunshine Biopharma Signs Research Agreement With the Jewish General Hospital to Advance the Development of Adva-27a Anticancer Compound
February 9, 2023
Sunshine Biopharma Announces Share Repurchase Program
January 18, 2023
Sunshine Biopharma’s Annual Letter to Shareholders
December 19, 2022
Sunshine Biopharma Enters Into a Collaboration Agreement with a Leading Lipid Nanoparticle Formulation Company for Its K1.1 Anticancer mRNA Project
November 15, 2022
Sunshine Biopharma Announces the Acquisition of Nora Pharma, Adding $10.7 Million in Revenue
October 19, 2022
Sunshine Biopharma Files Its Second Quarter Report With the SEC
August 3, 2022
Sunshine Biopharma Increases Support for Anti-Coronavirus Collaborative Research With the University of Arizona
July 27, 2022
Sunshine Biopharma, Inc. Announces Closing of $19.5 Million Private Placement Priced At-the-Market
April 27, 2022
Sunshine Biopharma, Inc. Announces Pricing of $19.5 Million Private Placement Priced At-the-Market
April 25, 2022
Sunshine Biopharma Files Patent Application Covering Recently Announced mRNA Molecules Found To Be Effective At Destroying Multidrug Resistant Cancer Cells
April 24, 2022
Sunshine Biopharma’s Newly Designed mRNA Molecules Prove Effective Against Multidrug Resistant Cancer Cells
April 4, 2022
Sunshine Biopharma, Inc. Announces Closing of $8.0 Million Private Placement Priced At-the-Market
March 13, 2022
Sunshine Biopharma, Inc. Announces Pricing of $8.0 Million Private Placement Priced At-the-Market
March 9, 2022
Sunshine Biopharma Expands Anti-Coronavirus Drug Development Program By Signing A Collaboration Agreement With The University Of Arizona
February 24, 2022
Sunshine Biopharma, Inc. Announces Closing of $8 Million Public Offering and Uplisting to the Nasdaq Capital Market
February 16, 2022
Sunshine Biopharma, Inc. Announces Pricing of $8 Million Public Offering and Uplisting to the Nasdaq Capital Market
February 14, 2022
Sunshine Biopharma Announces $1,361,000 in Debt Reduction
December 21, 2021
Sunshine Biopharma Expands Board of Directors
November 2, 2021
Sunshine Biopharma Files a Patent Application Covering mRNA Molecules for Treatment of Neurodegenerative Diseases
October 5, 2021
Sunshine Biopharma’s Coronavirus Treatment Anticipated to be Effective Against Delta and the Other Variants of Concern
August 11, 2021
Sunshine Biopharma Opens Twitter Account For Increased Shareholder Engagement
July 26, 2021
Sunshine Biopharma Receives $0.9 Million in Additional Funding From RB Capital
July 19, 2021
Sunshine Biopharma Employs mRNA Vaccine Technology to Expand Its Fight Against Multidrug Resistant Cancer
July 7, 2021
Sunshine Biopharma Mice Study for COVID-19 Treatment Progressing as Planned
June 8, 2021
Sunshine Biopharma’s Adva-27a Destroys Cancer Cells Expressing P-glycoprotein, a Marker Present in Over 50% of All Cancer Types
May 24, 2021
Sunshine Biopharma Eliminates $250,000 in Variable Rate Convertible Debt and Provides an Update on Status of OTCQB Uplisting
May 19, 2021
Sunshine Biopharma Reports Improved Cash Position in 2021Q1 Filing
May 12, 2021
Sunshine Biopharma Upgrades COVID-19 Provisional Patent Application to Full PCT Application
May 3, 2021
RB Capital Increases Investment in Sunshine Biopharma
April 21, 2021
Sunshine Biopharma Reports Favorable MTD Results for COVID-19 Treatment
April 18, 2021
Sunshine Biopharma Reaches $2,000,000+ Financing for Coronavirus Treatment
March 22, 2021
Decks
- Investor Presentation (February 2022)
Investor deck · 15 slides · Feb 8, 2022